Hippy Flip: Difference between revisions

From BurnZero
(Created page with " '''Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin / magic mushrooms is termed ''hippie flipping''.''' It is thought that by combining MDMA with psilocybin this may reduce challenging experiences and enhances positive experiences associated with the medicine. Some evidence points <ref name=":0">'''Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences'...")
 
mNo edit summary
 
Line 1: Line 1:


'''Co-use of 3,4-Methylenedioxy methamphetamine ([[MDMA]]) with [[psilocybin]] / [[magic mushrooms]] is termed ''hippie flipping''.''' It is thought that by combining MDMA with psilocybin this may reduce [[Adverse Psychedelic Effects|challenging experiences]] and enhances positive experiences associated with the medicine. Some evidence points <ref name=":0">'''Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences'''. Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. Published: 22 August 2023. Accessed on 17th January 2024 via: https://www.nature.com/articles/s41598-023-40856-5</ref>to the use of low dose MDMA (50–75 mg) with psilocybin associates with significantly lower levels of total challenging experience.
'''Co-use of 3,4-Methylenedioxy methamphetamine ([[MDMA]]) with [[psilocybin]] / [[magic mushrooms]] is termed ''hippy flipping''.''' It is thought that by combining MDMA with psilocybin this may reduce [[Adverse Psychedelic Effects|challenging experiences]] and enhances positive experiences associated with the medicine. Some evidence points <ref name=":0">'''Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences'''. Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. Published: 22 August 2023. Accessed on 17th January 2024 via: https://www.nature.com/articles/s41598-023-40856-5</ref>to the use of low dose MDMA (50–75 mg) with psilocybin associates with significantly lower levels of total challenging experience.


It is thought that the standard initial dose of [[MDMA]] (120mg) should be taken, 60 minutes prior to taking a 3g [[psilocybin]] dose. This ensures that the MDMA takes effect before the psilocybin which primes the trip to be less challenging<ref name=":0" />. This is then followed at 90 minutes by a 60 mg dose of MDMA to ensure that the shorter in duration MDMA effects do not wear off before the end of the 4 hour psilocybin trip.
It is thought that the standard initial dose of [[MDMA]] (120mg) should be taken, 60 minutes prior to taking a 3g [[psilocybin]] dose. This ensures that the MDMA takes effect before the psilocybin which primes the trip to be less challenging<ref name=":0" />. This is then followed at 90 minutes by a 60 mg dose of MDMA to ensure that the shorter in duration MDMA effects do not wear off before the end of the 4 hour psilocybin trip.

Latest revision as of 23:17, 2 May 2024

Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin / magic mushrooms is termed hippy flipping. It is thought that by combining MDMA with psilocybin this may reduce challenging experiences and enhances positive experiences associated with the medicine. Some evidence points [1]to the use of low dose MDMA (50–75 mg) with psilocybin associates with significantly lower levels of total challenging experience.

It is thought that the standard initial dose of MDMA (120mg) should be taken, 60 minutes prior to taking a 3g psilocybin dose. This ensures that the MDMA takes effect before the psilocybin which primes the trip to be less challenging[1]. This is then followed at 90 minutes by a 60 mg dose of MDMA to ensure that the shorter in duration MDMA effects do not wear off before the end of the 4 hour psilocybin trip.

References

  1. 1.0 1.1 Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross & Robin L. Carhart-Harris. Published: 22 August 2023. Accessed on 17th January 2024 via: https://www.nature.com/articles/s41598-023-40856-5

Share your opinion